1,25-Dihydroxyvitamin D3 regulates expression of LRP1 and RAGE in vitro and in vivo, enhancing Aβ1-40 brain-to-blood efflux and peripheral uptake transport

Neuroscience

Volumn 322, Issue , 2016, Pages 28-38

  Guo, Y X ^a,b   He, L Y ^a,b   Zhang, M ^a,b   Wang, F ^a,b   Liu, F ^a,b   Peng, W X ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

1,25(OH)2D3; Alzheimer's disease; Amyloid 1 40; LRP1; RAGE; VDR

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN[1-40]; CALCITRIOL; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; VITAMIN D RECEPTOR; AGER PROTEIN, HUMAN; AGER PROTEIN, MOUSE; AMYLOID BETA PROTEIN; CALCITRIOL RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; LRP1 PROTEIN, HUMAN; LRP1 PROTEIN, MOUSE; MESSENGER RNA; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CAPILLARY ENDOTHELIAL CELL; CELL HYPOXIA; CONTROLLED STUDY; HEPG2 CELL LINE; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METABOLIC CLEARANCE; MONOLAYER CULTURE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL LINE; DISEASE MODEL; DRUG EFFECTS; HEP-G2 CELL LINE; METABOLISM; PHYSIOLOGY; RANDOMIZATION;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; CALCITRIOL; CELL HYPOXIA; CELL LINE; DISEASE MODELS, ANIMAL; HEP G2 CELLS; HIPPOCAMPUS; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MALE; MICE; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RANDOM ALLOCATION; RECEPTORS, CALCITRIOL; RECEPTORS, LDL; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 84958971178     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2016.01.041     Document Type: Article

References (60)

1. Annweiler C., Brugg B., Peyrin J.M., Bartha R., Beauchet O. Combination of memantine and vitamin D prevents axon degeneration induced by amyloid-beta and glutamate. Neurobiol Aging 2014, 35:331-335.
2. Annweiler C., Dursun E., Feron F., Gezen-Ak D., Kalueff A.V., Littlejohns T., Llewellyn D.J., Millet P., Scott T., Tucker K.L., Yilmazer S., Beauchet O. 'Vitamin D and cognition in older adults': updated international recommendations. J Intern Med 2014.
3. Annweiler C., Herrmann F.R., Fantino B., Brugg B., Beauchet O. Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. Cogn Behav Neurol 2012, 25:121-127.
4. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., Zlokovic B.V. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007, 27:909-918.
5. Briones T.L., Darwish H. Vitamin D mitigates age-related cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden. J Neuroinflammation 2012, 9:244.
6. Brown R.C., Morris A.P., O'Neil R.G. Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 2007, 1130:17-30.
7. Bruggink K.A., Jongbloed W., Biemans E.A., Veerhuis R., Claassen J.A., Kuiperij H.B., Verbeek M.M. Amyloid-beta oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Anal Biochem 2013, 433:112-120.
8. Castano E.M., Prelli F., Soto C., Beavis R., Matsubara E., Shoji M., Frangione B. The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. J Biol Chem 1996, 271:32185-32191.
9. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005, 8:79-84.
10. Daulatzai M.A. Death by a thousand cuts in Alzheimer's disease: hypoxia-the prodrome. Neurotox Res 2013, 24:216-243.
11. Deane R., Zlokovic B.V. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2007, 4:191-197.
12. Deane R.J. Is RAGE still a therapeutic target for Alzheimer's disease?. Future Med Chem 2012, 4:915-925.
13. Donahue J.E., Flaherty S.L., Johanson C.E., Duncan J.A., Silverberg G.D., Miller M.C., Tavares R., Yang W., Wu Q., Sabo E., Hovanesian V., Stopa E.G. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 2006, 112:405-415.
14. Durk M.R., Chan G.N., Campos C.R., Peart J.C., Chow E.C., Lee E., Cannon R.E., Bendayan R., Miller D.S., Pang K.S. 1alpha,25-Dihydroxyvitamin D3-liganded vitamin D receptor increases expression and transport activity of P-glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells. J Neurochem 2012, 123:944-953.
15. Durk M.R., Han K., Chow E.C., Ahrens R., Henderson J.T., Fraser P.E., Pang K.S. 1alpha,25-Dihydroxyvitamin D3 reduces cerebral amyloid-beta accumulation and improves cognition in mouse models of Alzheimer's disease. J Neurosci 2014, 34:7091-7101.
16. Dursun E., Gezen-Ak D., Yilmazer S. A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid-beta and preventing the amyloid-beta induced alterations by vitamin D in cortical neurons. J Alzheimer's Dis: JAD 2011, 23:207-219.
17. Dursun E., Gezen-Ak D., Yilmazer S. A new mechanism for amyloid-beta induction of iNOS: vitamin D-VDR pathway disruption. J Alzheimer's Dis: JAD 2013, 36:459-474.
18. Gezen-Ak D., Dursun E., Yilmazer S. The effects of vitamin D receptor silencing on the expression of LVSCC-A1C and LVSCC-A1D and the release of NGF in cortical neurons. PLoS ONE 2011, 6:e17553.
19. Ghiso J., Shayo M., Calero M., Ng D., Tomidokoro Y., Gandy S., Rostagno A., Frangione B. Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem 2004, 279:45897-45908.
20. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (New York, NY) 2002, 297:353-356.
21. Ito S., Ohtsuki S., Nezu Y., Koitabashi Y., Murata S., Terasaki T. 1Alpha,25-dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-beta peptide(1-40) from mouse brain across the blood-brain barrier. Fluids Barriers CNS 2011, 8:20.
22. Jedlitschky G., Grube M., Mosyagin I., Kroemer H.K., Vogelgesang S. Targeting CNS transporters for treatment of neurodegenerative diseases. Curr Pharm Des 2014, 20:1523-1533.
23. Kuningas M., Mooijaart S.P., Jolles J., Slagboom P.E., Westendorp R.G., van Heemst D. VDR gene variants associate with cognitive function and depressive symptoms in old age. Neurobiol Aging 2009, 30:466-473.
24. Lauren J., Gimbel D.A., Nygaard H.B., Gilbert J.W., Strittmatter S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457:1128-1132.
25. Lee T.W., Kao Y.H., Lee T.I., Chang C.J., Lien G.S., Chen Y.J. Calcitriol modulates receptor for advanced glycation end products (RAGE) in diabetic hearts. Int J Cardiol 2014, 173:236-241.
26. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
27. Lisse T.S., Chun R.F., Rieger S., Adams J.S., Hewison M. Vitamin D activation of functionally distinct regulatory miRNAs in primary human osteoblasts. J Bone Miner Res 2013, 28:1478-1488.
28. Littlejohns T.J., Henley W.E., Lang I.A., Annweiler C., Beauchet O., Chaves P.H., Fried L., Kestenbaum B.R., Kuller L.H., Langa K.M., Lopez O.L., Kos K., Soni M., Llewellyn D.J. Vitamin D and the risk of dementia and Alzheimer disease. Neurology 2014, 83:920-928.
29. Mark K.S., Davis T.P. Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol 2002, 282:H1485-1494.
30. Martin A.M., Kuhlmann C., Trossbach S., Jaeger S., Waldron E., Roebroek A., Luhmann H.J., Laatsch A., Weggen S., Lessmann V., Pietrzik C.U. The functional role of the second NPXY motif of the LRP1 beta-chain in tissue-type plasminogen activator-mediated activation of N-methyl-D-aspartate receptors. J Biol Chem 2008, 283:12004-12013.
31. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., Yarasheski K.E., Bateman R.J. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (New York, NY) 2010, 330:1774.
32. Miller M.C., Tavares R., Johanson C.E., Hovanesian V., Donahue J.E., Gonzalez L., Silverberg G.D., Stopa E.G. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res 2008, 1230:273-280.
33. Mizwicki M.T., Liu G., Fiala M., Magpantay L., Sayre J., Siani A., Mahanian M., Weitzman R., Hayden E.Y., Rosenthal M.J., Nemere I., Ringman J., Teplow D.B. 1Alpha,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-beta phagocytosis and inflammation in Alzheimer's disease patients. J Alzheimer's Dis: JAD 2013, 34:155-170.
34. Mizwicki M.T., Menegaz D., Zhang J., Barrientos-Duran A., Tse S., Cashman J.R., Griffin P.R., Fiala M. Genomic and nongenomic signaling induced by 1alpha,25(OH)2-vitamin D3 promotes the recovery of amyloid-beta phagocytosis by Alzheimer's disease macrophages. J Alzheimer's Dis: JAD 2012, 29:51-62.
35. Mohamed L.A., Kaddoumi A. In vitro investigation of amyloid-beta hepatobiliary disposition in sandwich-cultured primary rat hepatocytes. Drug Metab Dispos 2013, 41:1787-1796.
36. Mucke L. Neuroscience: Alzheimer's disease. Nature 2009, 461:895-897.
37. Neve R.L., Robakis N.K. Alzheimer's disease: a re-examination of the amyloid hypothesis. Trends Neurosci 1998, 21:15-19.
38. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 2010, 13:812-818.
39. Pappolla M., Sambamurti K., Vidal R., Pacheco-Quinto J., Poeggeler B., Matsubara E. Evidence for lymphatic Abeta clearance in Alzheimer's transgenic mice. Neurobiol Dis 2014, 71:215-219.
40. Pflanzner T., Kuhlmann C.R., Pietrzik C.U. Blood-brain-barrier models for the investigation of transporter- and receptor-mediated amyloid-beta clearance in Alzheimer's disease. Curr Alzheimer Res 2010, 7:578-590.
41. Qosa H., Abuasal B.S., Romero I.A., Weksler B., Couraud P.O., Keller J.N., Kaddoumi A. Differences in amyloid-beta clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Neuropharmacology 2014, 79:668-678.
42. Sagare A.P., Deane R., Zlokovic B.V. Low-density lipoprotein receptor-related protein 1: a physiological Abeta homeostatic mechanism with multiple therapeutic opportunities. Pharmacol Ther 2012, 136:94-105.
43. Saito S., Ihara M. New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. Front Aging Neurosci 2014, 6:290.
44. Sambamurti K., Greig N.H., Utsuki T., Barnwell E.L., Sharma E., Mazell C., Bhat N.R., Kindy M.S., Lahiri D.K., Pappolla M.A. Targets for AD treatment: conflicting messages from γ-secretase inhibitors. J Neurochem 2011, 117:359-374.
45. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008, 14:837-842.
46. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Investig 2000, 106:1489-1499.
47. Slowik A., Merres J., Elfgen A., Jansen S., Mohr F., Wruck C.J., Pufe T., Brandenburg L.O. Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE) - and amyloid beta 1-42-induced signal transduction in glial cells. Mol Neurodegener 2012, 7:55.
48. Smith C.C., Betteridge D.J. Plasma beta-amyloid (A beta) 40 concentration, lipid status and age in humans. Neurosci Lett 2004, 367:48-50.
49. Stanimirovic D.B., Friedman A. Pathophysiology of the neurovascular unit: disease cause or consequence?. J Cereb Blood Flow Metab 2012, 32:1207-1221.
50. Sutcliffe J.G., Hedlund P.B., Thomas E.A., Bloom F.E., Hilbush B.S. Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer's disease. J Neurosci Res 2011, 89:808-814.
51. Talmor-Barkan Y., Bernheim J., Green J., Benchetrit S., Rashid G. Calcitriol counteracts endothelial cell pro-inflammatory processes in a chronic kidney disease-like environment. J Steroid Biochem Mol Biol 2011, 124:19-24.
52. Tamaki C., Ohtsuki S., Iwatsubo T., Hashimoto T., Yamada K., Yabuki C., Terasaki T. Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res 2006, 23:1407-1416.
53. Verbeek M.M., Ruiter D.J., de Waal R.M. The role of amyloid in the pathogenesis of Alzheimer's disease. Biol Chem 1997, 378:937-950.
54. Waldron E., Heilig C., Schweitzer A., Nadella N., Jaeger S., Martin A.M., Weggen S., Brix K., Pietrzik C.U. LRP1 modulates APP trafficking along early compartments of the secretory pathway. Neurobiol Dis 2008, 31:188-197.
55. Yan F.L., Zheng Y., Zhao F.D. Effects of ginkgo biloba extract EGb761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia. Acta Neuropathol 2008, 116:529-535.
56. Yu J., Gattoni-Celli M., Zhu H., Bhat N.R., Sambamurti K., Gattoni-Celli S., Kindy M.S. Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of AbetaPP transgenic mice. J Alzheimer's Dis: JAD 2011, 25:295-307.
57. Zhang X., Le W. Pathological role of hypoxia in Alzheimer's disease. Exp Neurol 2010, 223:299-303.
58. Zhang X., Li L., Zhang X., Xie W., Li L., Yang D., Heng X., Du Y., Doody R.S., Le W. Prenatal hypoxia may aggravate the cognitive impairment and Alzheimer's disease neuropathology in APPSwe/PS1A246E transgenic mice. Neurobiol Aging 2013, 34:663-678.
59. Zitman-Gal T., Golan E., Green J., Bernheim J., Benchetrit S. Vitamin D receptor activation in a diabetic-like environment: potential role in the activity of the endothelial pro-inflammatory and thioredoxin pathways. J Steroid Biochem Mol Biol 2012, 132:1-7.
60. Zlokovic B.V., Yamada S., Holtzman D., Ghiso J., Frangione B. Clearance of amyloid beta-peptide from brain: transport or metabolism?. Nat Med 2000, 6:718-719.